178 related articles for article (PubMed ID: 22077140)
1. Transcriptional control of HIV replication by multiple modulators and their implication for a novel antiviral therapy.
Victoriano AF; Okamoto T
AIDS Res Hum Retroviruses; 2012 Feb; 28(2):125-38. PubMed ID: 22077140
[TBL] [Abstract][Full Text] [Related]
2. Recent status of HIV-1 gene expression inhibitors.
Baba M
Antiviral Res; 2006 Sep; 71(2-3):301-6. PubMed ID: 16488488
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of HIV-1 gene expression and transcription.
Baba M
Curr Top Med Chem; 2004; 4(9):871-82. PubMed ID: 15134546
[TBL] [Abstract][Full Text] [Related]
4. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
Quivy V; De Walque S; Van Lint C
Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
[TBL] [Abstract][Full Text] [Related]
5. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway.
Márquez N; Sancho R; Bedoya LM; Alcamí J; López-Pérez JL; Feliciano AS; Fiebich BL; Muñoz E
Antiviral Res; 2005 Jun; 66(2-3):137-45. PubMed ID: 15911030
[TBL] [Abstract][Full Text] [Related]
6. A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication.
Massari S; Daelemans D; Barreca ML; Knezevich A; Sabatini S; Cecchetti V; Marcello A; Pannecouque C; Tabarrini O
J Med Chem; 2010 Jan; 53(2):641-8. PubMed ID: 19958026
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.
Okamoto H; Cujec TP; Okamoto M; Peterlin BM; Baba M; Okamoto T
Virology; 2000 Jul; 272(2):402-8. PubMed ID: 10873784
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways.
Leghmari K; Bennasser Y; Bahraoui E
Eur J Cell Biol; 2008 Dec; 87(12):947-62. PubMed ID: 18760861
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
[TBL] [Abstract][Full Text] [Related]
10. 4-Phenylcoumarins as HIV transcription inhibitors.
Bedoya LM; Beltrán M; Sancho R; Olmedo DA; Sánchez-Palomino S; del Olmo E; López-Pérez JL; Muñoz E; San Feliciano A; Alcamí J
Bioorg Med Chem Lett; 2005 Oct; 15(20):4447-50. PubMed ID: 16137881
[TBL] [Abstract][Full Text] [Related]
11. Regulation of expression of human immunodeficiency virus.
Pavlakis GN; Felber BK
New Biol; 1990 Jan; 2(1):20-31. PubMed ID: 2078551
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator.
Roof P; Ricci M; Genin P; Montano MA; Essex M; Wainberg MA; Gatignol A; Hiscott J
Virology; 2002 Apr; 296(1):77-83. PubMed ID: 12036319
[TBL] [Abstract][Full Text] [Related]
13. The HIV-1 Tat transactivator protein: a therapeutic target?
Fulcher AJ; Jans DA
IUBMB Life; 2003 Dec; 55(12):669-80. PubMed ID: 14769003
[TBL] [Abstract][Full Text] [Related]
14. An allosteric drug, o,o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B.
Shoji S; Furuishi K; Ogata A; Yamataka K; Tachibana K; Mukai R; Uda A; Harano K; Matsushita S; Misumi S
Biochem Biophys Res Commun; 1998 Aug; 249(3):745-53. PubMed ID: 9731208
[TBL] [Abstract][Full Text] [Related]
15. Taking out Tat.
Jones KA
Nat Biotechnol; 1996 Nov; 14(11):1542-3. PubMed ID: 9634816
[No Abstract] [Full Text] [Related]
16. Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation.
Balachandran A; Wong R; Stoilov P; Pan S; Blencowe B; Cheung P; Harrigan PR; Cochrane A
Retrovirology; 2017 Jan; 14(1):7. PubMed ID: 28122580
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of tumor necrosis factor-alpha and herpes simplex virus type 1 on the Tat-targeted inhibition of human immunodeficiency virus type 1 replication.
Popik W; Pitha PM
Virology; 1994 Aug; 202(2):521-9. PubMed ID: 8030218
[TBL] [Abstract][Full Text] [Related]
18. Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants.
de Arellano ER; Alcamí J; López M; Soriano V; Holguín A
Antiviral Res; 2010 Nov; 88(2):152-9. PubMed ID: 20713090
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells.
Wires ES; Alvarez D; Dobrowolski C; Wang Y; Morales M; Karn J; Harvey BK
J Neurovirol; 2012 Oct; 18(5):400-10. PubMed ID: 22618514
[TBL] [Abstract][Full Text] [Related]
20. HDAC1/NFκB pathway is involved in curcumin inhibiting of Tat-mediated long terminal repeat transactivation.
Zhang HS; Ruan Z; Sang WW
J Cell Physiol; 2011 Dec; 226(12):3385-91. PubMed ID: 21344388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
